Advice
following an abbreviated submission:
diamorphine hydrochloride (Ayendi®) is accepted for use within NHS Scotland.
Indication under review: treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring.
Unlicensed intranasal diamorphine has been used in the NHS in Scotland for the treatment of severe pain in children in the emergency setting. The availability of diamorphine hydrochloride nasal spray (Ayendi®) provides a licensed preparation.
Download detailed advice111KB (PDF)
Medicine details
- Medicine name:
- diamorphine hydrochloride (Ayendi)
- SMC ID:
- 1172/16
- Indication:
- Treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring.
- Pharmaceutical company
- Wockhardt UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 August 2016